Camac Partners Calls on TuSimple to Take Long Overdue Step of Monetizing Remaining Assets and Returning Capital to Shareholders
Camac Partners, LLC (together with its affiliates, “Camac”), a 5.6% shareholder of TuSimple Holdings Inc. (OTCMKTS: TSPH) (“TuSimple” or the “Company”), today released a letter it recently sent to the Company’s Board of Directors (the “Board”).
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed concerns regarding the Company’s sizable trading price discount relative to its cash on hand and the Board of Directors’ (the “Board”) decision to conduct a highly dilutive equity capital raise following the emergence of four separate Schedule 13D filers.
